Study of a new drug for Stargardt disease
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 45 years old
- You have a clinical diagnosis of Stargardt disease with a confirmed genetic mutation
- You have not taken vitamin A, beta-carotene, or liver supplements in the past 30 days
- You are not pregnant or planning to become pregnant, and agree to use birth control if needed
- You have not been in another Stargardt disease drug trial in the past 6 months or any gene/cell therapy trial ever
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This study tests a single injection of ASP2020 in the eye to see if it is safe and if it can help improve vision for people with Stargardt disease or similar inherited eye conditions.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
Hear when a new Stargardt Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.